Product Program year 2025 Source: CMS Open Payments

Erleada

Drug Oncology

NDC 59676-600-12

Open in the dashboard

General payments

$16,750,045

168,541 payments

Research payments

$60,201,511

5,542 payments

Through program year 2025, $16,750,045 in general payments and $60,201,511 in research payments were reported against Erleada (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $2,214,377 34,374
2025 Research $16,114,632 1,590
2024 General $3,017,719 27,123
2024 Research $18,202,743 1,503
2023 General $2,392,691 25,298
2023 Research $10,715,433 1,126
2022 General $2,652,181 23,720
2022 Research $12,094,089 1,248
2021 General $1,769,545 18,929
2021 Research $1,786,086 34
2020 General $1,305,553 9,591
2020 Research $1,038,239 31
2019 General $3,397,980 29,506
2019 Research $250,289 10

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $14,501,706 159,873 payments
  2. Janssen Scientific Affairs, LLC $1,073,848 4,098 payments
  3. Janssen Research & Development, LLC $561,816 173 payments
  4. Janssen Global Services, LLC $309,454 184 payments
  5. Janssen Pharmaceuticals, Inc $278,135 4,149 payments
  6. Johnson & Johnson Health Care Systems Inc. $25,085 64 payments
Top recipients General payments · program year 2025
  1. Philip Lim Diagnostic Radiology · Danville, PA $129,250 6% · 4 payments
  2. Ochsner Clinic Foundation Teaching hospital · LA $68,500 3% · 4 payments
  3. Cleveland Clinic Hospital Teaching hospital · OH $50,000 2% · 1 payment
  4. Emory University Hospital Teaching hospital · GA $40,000 2% · 2 payments
  5. Stephen Freedland Urology · West Hollywood, CA $31,500 1% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Urology $586,605 32% · 3,220 practitioners
  2. Hematology & Oncology Internal Medicine $330,880 18% · 1,778 practitioners
  3. Medical Oncology Internal Medicine $219,940 12% · 483 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $150,518 8% · 1,502 practitioners
  5. Diagnostic Radiology Radiology $130,102 7% · 28 practitioners

The top 5 of 111 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Pennsylvania $223,521 10% · 546 recipients
  2. California $206,826 9% · 1,042 recipients
  3. Florida $190,410 9% · 1,225 recipients
  4. New York $150,103 7% · 713 recipients
  5. Texas $128,752 6% · 919 recipients

The top 5 of 53 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

80,841

Prescriptions dispensed, refills included

Drug cost

$1,166,878,397

Paid at the pharmacy, in all

Prescribers

2,428

With 11 or more claims of it

Medicare Part D drugs matched to ERLEADA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Erleada Apalutamide Same name 2,428 80,841 $1,166,878,397

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
William Townsend Urology NC 662 $9,575,773 $99
Alexander Engelman Radiation Oncology FL 660 $9,623,883 $2,799
Aaron Berger Urology IL 617 $8,789,858 $22,953
Ryan Malone Urology IN 588 $8,393,481 $2,398
David Taylor Urology NJ 550 $7,803,408 $5,701

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
168,541 general · 5,542 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record